We’re happy to share the recently published study, “Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study”. This important Canadian database study examines patients aged 50 and under, an age group that represents only 10% of myeloma cases and is often underrepresented in research. 

Analyzing 493 patients treated between 2010 and 2022, the study reports a median progression-free survival of 45 months (median overall survival has not yet been reached).

Despite treatment advancements, the findings highlight the urgent need for innovative therapies to achieve deeper and longer-lasting responses in this population.

This work was supported by Myeloma Canada through the 2023 Aldo Del Col Research Grant competition, and the Maryse and William Brock Chair in Applied Research into Stem Cell Transplantation held by Dr Jean Roy at Université de Montréal. 

Read the article.